AUTHORS

Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

Putting My Covered Call Strategy to Work With 2 Dinged Biotech Stocks

Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.

Averaging Down: How to Invest in Small-Cap Biotech and Not Lose Your Shirt

Use buy-write or covered call orders with just out-of-the-money calls to average down in core small-cap holdings when inevitable declines occur.

Insiders at These Companies Didn't Wait for Cyber Monday to Buy

A handful of midstream energy companies and a travel giant have seen insiders purchase their shares in recent weeks.

3 Tech Themes That Played Out In 2019

The trio involves unicorns, the FAANG stocks and blockchain.

Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets

The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.

Energy Sector's Lack of Energy Requires Selective Investing

There are a few plays to consider in the energy arena, but it still looks like a place to be underweight going into 2020.

2 Small Biotechs to Put on Your 2020 Radar

Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.

2 Biotech Stocks to Check Out After Karuna Therapeutics' Rocket-Like Surge

Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.

Medicines Co. and Novartis

2 Small-Cap Biotech Stocks I Continue to Like

Both these names reported third-quarter results last week.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight